American Oncology Network, Inc. AONC · OTC
$22.01 +0.05% (+$0.01)
Summary
35 / 100 · Bulios Score
What speaks for it
- Revenue grew by 23% a year over the last 3 years.
- The price moves less than the market (beta 0.53).
What to watch
- The company made a loss over the last 12 months.
- Repaying its net debt would take 46.6 years of operating profit.
- It passes only 3 of the 9 points of the Piotroski financial health test.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Fairly pricedThe company made a loss over the last 12 months, so there is no profit to set the price against.
Valuation in detailIs it growing?
Yes, fastRevenue (USD)
Diluted EPS (USD)
Revenue grew by 23% a year over the last 3 years.
Growth in detailDoes it make money?
PoorlyOver the last 12 months it made a loss of $3.97M.
Profitability in detailIs it financially healthy?
YesRepaying all its debt would take 2.8 years of free cash flow. Its debt is larger than its cash. The debt score is low because of the debt-to-equity ratio (7.9x).
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
No coverageNo analyst covers this stock.
Analysts in detailWhat does it earn on?
Fiscal year 2024By product
- Product and Service, Other 100%
By region
The company reports no revenue by region.
Product and Service, Other brings in 100% of revenue.
Segments in detail